Remove 2017 Remove Healthcare Remove Safety
article thumbnail

Bridging the healthcare digital divide: a gradual approach to adopting ePI

European Pharmaceutical Review

Within the EU, patient information leaflets (PILs) are not merely a regulatory requirement but a cornerstone of patient safety. They are vital to ensuring the safe and effective use of medicines, making them an integral part of healthcare in Europe. percent as EU average with some Member States as high as 25 percent).

article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

Meanwhile, the top 25 pharmaceutical companies reported a “healthy average operating margin of 22 percent” at the end of 2017, according to an analysis by GlobalData. About 40 percent of drugs fail in preliminary Phase I studies, which assess a drug’s safety in humans and typically cost just $25 million.

Pharma 255
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drug pricing increases are disgraceful

World of DTC Marketing

Meanwhile, the top 25 pharmaceutical companies reported a “healthy average operating margin of 22 percent” at the end of 2017, according to an analysis by GlobalData. About 40 percent of drugs fail in preliminary Phase I studies, which assess a drug’s safety in humans and typically cost just $25 million a drug.

Insurance 181
article thumbnail

Developing the EU’s first intestinal microbiota-based biologic

European Pharmaceutical Review

The main objective was to evaluate the efficacy and safety of MBK-01 compared to fidaxomicin, providing significant insights into the potential of MBK-01 as a treatment for primary or recurrent CDI and contributing to the advancement of microbiome-based therapies. 2017; 55(7):1998-2008. McDonald CL, Gerding DN, Johnson S, et al.

Safety 111
article thumbnail

Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets

PM360

In 2017, Algeria imposed importation restrictions on medicinal products that could be manufactured domestically, forcing manufacturers to establish local manufacturing facilities or to work with a contract manufacturing organization (CMO). To illustrate, let’s take the example of protectionist policies. References: 1.

article thumbnail

Towards ‘smart’ vaccine development and manufacturing

European Pharmaceutical Review

THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis. This can drive informed decisions and strategies to enhance the safety, quality and efficiency of the manufacturing process.

article thumbnail

The Caregiver Vertical: How Pharma Engages

Pharma Marketing Network

With an estimated 65 million people serving as caregivers, 1 the role is now a factor in an ever-increasing list of healthcare priorities. If caregiving is positioned as an essential service and caregivers are counted among healthcare’s front-line service providers, 4 does it follow caregivers are a viable healthcare vertical?

Pharma 98